Fosfomycin

ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Fosfomycin is an ofp drug catalogued in DrugCentral. It was first approved by the FDA in 1996. DrugCentral lists 4 molecular targets, including murA, murA and murA1. Recorded indications include Enterococcus Urinary Tract Infection, Escherichia coli urinary tract infection and Urinary tract infectious disease.

• Approval status: ofp (first approved 1996 by the FDA).
• Molecular targets: murA, murA, murA1 and murA2 (4 listed in DrugCentral).
• Indications: Enterococcus Urinary Tract Infection, Escherichia coli urinary tract infection and Urinary tract infectious disease.
• ATC code: J01XX01 (Other antibacterials).
• Molecular formula: C3H7O4P; molecular weight 138.06 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

• Enterococcus Urinary Tract Infection
• Escherichia coli urinary tract infection
• Urinary tract infectious disease

Contraindications (2)

• Kidney disease
• Pseudomembranous enterocolitis

Mechanism & targets

Molecular targets (4)

Target	Gene	Action	Activity
UDP-N-acetylglucosamine 1-carboxyvinyltransferase	murA	inhibitor	IC50 7.00
UDP-N-acetylglucosamine 1-carboxyvinyltransferase	murA	unknown	IC50 4.98
UDP-N-acetylglucosamine 1-carboxyvinyltransferase 1	murA1	unknown	—
UDP-N-acetylglucosamine 1-carboxyvinyltransferase 2	murA2	unknown	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1996-12-19	FDA	—	ZAMBON SPA

ATC classification

ATC code	Therapeutic hierarchy
J01XX01	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER ANTIBACTERIALS › Other antibacterials
S02AA17	SENSORY ORGANS › OTOLOGICALS › ANTIINFECTIVES › Antiinfectives

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Cardiospasm	793.1
Palmoplantar keratoderma	769.2
Pruritus genital	729.5
Sleep terror	723.2
Atrial tachycardia	685.7
Carotid artery occlusion	670.2
Tension headache	654.9
Anosmia	609.9
Facial pain	587.0
Immunisation	549.1
Pain of skin	522.1
Subarachnoid haemorrhage	476.1

Chemical structure

• Molecular formula: C₃H₇O₄P
• Molecular weight: 138.06 g/mol
• CAS number: —
• InChIKey: YMDXZJFXQJVXBF-STHAYSLISA-N
• PubChem CID: 446987

C[C@@H]1O[C@@H]1P(O)(O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Fosfomycin used for?

DrugCentral lists the following indications for Fosfomycin: Enterococcus Urinary Tract Infection, Escherichia coli urinary tract infection and Urinary tract infectious disease.

How does Fosfomycin work?

Its molecular targets in DrugCentral include murA (inhibitor), murA, murA1 and murA2.

When was Fosfomycin first approved?

Fosfomycin was first approved by the FDA in 1996.

What is the chemical formula of Fosfomycin?

Fosfomycin has the molecular formula C3H7O4P and a molecular weight of 138.06 g/mol.

Sources

• DrugCentral drug card 1243 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1200331 — compound record and bioactivity
• PubChem CID 446987 — chemical identifiers
• DrugBank DB00828 — drug record
• FDA UNII 2N81MY12TE — substance identity
• DailyMed: FDA labels for Fosfomycin — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.